Assess ability of the drug magnesium sulphate when added with a local anaesthesia agent like ropivacaine and compare it to ropivacaine alone to alleviate pain while being continuously given in the post operative surgical site after uterus removal surgery

To assess the analgesic efficacy of adjuvant magnesium sulphate added with Ropivacaine over Ropivacaine alone as continuous infiltration for total abdominal hysterectomy wounds: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/07/009176

Enrollment

Registered

2017-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- POST OPEN HYSTERECTOMY

Interventions

Intervention1: Wound infiltration catheter in open hysterectomy wounds: Infiltration with Ropivacaine with and without magnesium sulphate Intervention2: ropivacaine with magnesium sulphate: continuous

Eligibility

Inclusion criteria

Inclusion criteria: a) Female patients 18yrs and above; b) Belonging to ASA physical status 1&2; c) Patients undergoing open hysterectomy for benign conditions d) Patients operated with a transverse incision

Exclusion criteria

Exclusion criteria: a) Patients with malignancy;b) On systemic analgesic medication for some other ailment;c) Patients refusal to have catheter; d) Known allergy to any of the study drugs

Design outcomes

Primary

Measure	Time frame
Total analgesics (Morphine) consumed by the groups during the first 48 hoursTimepoint: First 48 hours	—

Secondary

Measure	Time frame
VRSP at rest and mobilization at 48 hours Patient satisfaction score at 48 hours Wound Quality of Life at 7 days Timepoint: 48HRS TO 7 DAYS	—

Countries

India

Contacts

Public ContactDevalina Goswami

drdevalina@gmail.com011-26593212

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026